Brand Reference: Cialis, Adcirca
| Metric | Verified Benchmark | Source |
|---|---|---|
| Tadalafil RxNorm Concept ID | 358263 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $0.0680 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $165.00 / mo | CMS NADAC + U.S. Retail Markup Index |
| Mark Cuban Cost Plus Wholesale Price | $5.90 / mo | Cost Plus Drugs Wholesale Feed |
| Community Mean Out-of-Pocket Paid | $7.50 / mo | 64 Zero-PHI Verified Patient Logs |
Selectively inhibits cyclic guanosine monophosphate (cGMP)-specific PDE5 across corpus cavernosum, prostatic smooth muscle, bladder detrusor, and systemic vascular endothelium (>700-fold selectivity over retinal PDE6)—enhancing nitric-oxide-driven microperfusion for 36 hours.
CMS National Average Drug Acquisition Cost (NADAC) tracking places Tadalafil (Cialis / Adcirca, RxCUI 358263) at $0.0680 per unit, whereas walk-in chain pharmacies bill cash patients an average of $165.00 monthly—creating a 96% ($159.10/mo) wholesale arbitrage spread down to $5.90.
Systemic exposure to Tadalafil reflects > 80% oral (completely unaffected by high-fat food or alcohol) absorption kinetics and hepatic cyp3a4 oxidation to inactive methylcatechol glucuronide, sustaining receptor engagement across a 17.5 hours (36-hour clinical responsiveness window) half-life window (30–60 minutes on-demand; 5 days daily steady state response profile).
Dosing protocols (2.5 mg PO once daily or 5 mg PO once daily (dual ED + BPH + endothelial protocol) or 10 mg PO PRN or 20 mg PO PRN) balance efficacy (96.10% patient satisfaction across 64 logs) against nasal mucosal congestion (14% of reports), pde11 lumbar/gluteal ache (days 2–4) (11% of reports), mild reflux (8% of reports), with strict avoidance in any organic nitrate (nitroglycerin/isosorbide) within 48 hours; guanylate cyclase stimulators (riociguat); unstable angina.
Across 64 verified cash-pay logs, Tadalafil achieves a 96.10% Worth-It rating with out-of-pocket spend averaging $7.50/mo versus $165.00/mo walk-in retail.
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Switched to Cost Plus Drugs at 2.5 mg PO once daily for Tadalafil; monthly out-of-pocket dropped to $5.19 compared with $165.00 retail.
Completed 10 weeks on Tadalafil (5 mg PO once daily (dual ED + BPH + endothelial protocol)). Zero notable side effects on steady dosing.
Consistent biomarker response on 10 mg PO PRN Tadalafil sourced via Local Pharmacy ($6.84/mo cash pay without insurance prior authorization).